Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib

详细信息    查看全文

• 作者：Alfonso Quintá ; s-Cardama ; ^{aquintas@mdanderson.org} ; Elias J. Jabbour
• 关键词：Chronic myeloid leukemia ; Imatinib ; Nilotinib ; Dasatinib ; Drug resistance ; Adverse drug event
• 刊名：Leukemia Research
• 出版年：2013
• 出版时间：May, 2013
• 年：2013
• 卷：37
• 期：5
• 页码：487-495
• 全文大小：277 K

文摘

Clinical evidence in chronic myeloid leukemia demonstrates a significant link between optimal response to tyrosine kinase inhibitor (TKI) therapy and favorable clinical outcome. For patients with suboptimal response to first-line TKI, clinical data show that a considerable proportion can be rescued by second-line TKI. Practice guidelines now recommend that clinicians consider a switch in TKI for patients with suboptimal response as early as 3 months after first-line TKI initiation, thus allowing clinicians to intervene in a timely manner and consider the potential benefit of a switch in TKI therapy.